Abstract:Objective: To study the pharmacokinetics of a single dose of cefoperazone/tazobactam compound injection in health volunteers. Methods: Ten healthy volunteers were selected to receive a single dose of cefoperazone/tazobactam compound or cefoperazone alone within 30min infusion in an open randomized crossover study. The concentration of cefoperazone and tazobactam in serum and urine were determined by a high - performance liquid chromatography (HPLC) method. Results: Pharmacokinetic parameters were based on an open two - compartment model analyzed by using 3P97 and the results of HPLC method were as follows: the mean peak concentration (C max) of cefoperazone alone or in compound at the end of infusion were (181.52 ± 41.66) and (176.21 ± 32.66) mg/L respectively. The area under the concentration - time curve AUC 0.5-12 were (351.96 ± 54.53) and (336.31 ± 54.93)mg · h/L; AUC 0-12 were (402.21 ± 57.63) and (376.64 ± 55.18)mg · h/L;AUC 0-inf were (413.47 ± 59.06) and (395.83 ± 62.08)mg · h/L, respectively. The mean plasma elimination half-life(t 1/2β) were (2.23 ± 0.67) and (2.28 ± 0.61) h, respectively. The mean clearances(CL) were (4.06 ± 0.61) and (4.30 ± 0.79)1/h, respectively. The volume of distribution (Vd) were (6.52 ± 2.55) and (6.86 ± 3.27) L. respectively. The mean peak concentration(C max) of tazobactam at the end of infusion was (20.31 ± 4.76)mg/L. The area under the concentration - time curve AUC 0.5-5 was (12.96 ± 2.40) mg · h/L, AUC 0-5 was (18.45 ± 3.52) mg · h/L, AUC 0-inf was (19.42 ± 3.67) mg · h/L. The mean plasma elimination half - life(t 1/2β) was (0.84 ± 0.28)h. The mean clearances (CL) was (22.36 ± 4.08)l/h. The volume of distribution (Vd) was (11.49 ± 5.60) L. Urinary recovery rates of cefoperazone in cefoperazone/tazobactam and cefoperazone alone were (22.92 ± 7.79)% and (21.00 ± 7.33)% in 24h. Urinary recovery rate of tazobactam in cefoperazone/tazobactam was (60.56 ± 19.37)%. Conclusions: All volunteers were well tolerated in the single dose of 1600mg cefoperazone and cefoperazone/tazobactam (1600mg/400mg) given by iv infusion in 30min. Cefoperazone and tazobactam had no interaction when given together.

Study on the pharmacokinetics of Cefazolin and HPLC assay for the serum concentration

Development of Thin-Layer Chromatography–Densitometric Procedure for Qualitative and Quantitative Analyses and Stability Studies of Cefazolin

Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandam mass spectrometry.

Determination of Cefaclor in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography with UV Detection and Its Application to the Bioequivalence Studies

Pharmacokinetic study and rapid determination of ceftazidime in serum and urine with column packed by 3μm particle

Pharmacokinetics of Multiple-Dose Cefazedone Sodium in Chinese Healthy Subjects

Determination of ceftizoxime in ceftizoxime sodium for injection / sodium chloride injection by high performance liquid chromatography

Comparison of high performance liquid chromatography and bioassay for determination of ciprofloxacin in serum

The Kinetics of Cefuroxime in Ascitic and Pleural Fluid.

Pharmacokinetics study on cefoperazone and tazobactam compound injection in health volunteers

Verification of ceftriaxone and determination of its concentration in blood serum by capillary electrophoresis in surgical patients

Determination of Caderofloxacin Concentration in Healthy Human Plasma by RP-HPLC

Study on clinical pharmacokinetics of cefpiramide

Target Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive Staphylococcus aureus Infections: A Prospective Cohort Study

Pharmacokinetic study of cefazolin and ceftazidime in the elderly

Adequate cefazolin therapy for critically ill patients: can we predict active concentrations from given protein-binding data?

Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?

Study on Clinical Pharmacokinetics and Pharmacodynamics of Cefprozil

Simultaneous determination of serum concentration of amoxicillin and clavulanate by HPLC with fluorescence detection

Study of Pharmacokinetics and LC-MS/MS Method of Blood Concentration of Clarithromycin

A Validated HPLC-MS/MS Method for the Quantification of Caderofloxacin in Human Plasma and Its Application to a Clinical Pharmacokinetic Study